158 related articles for article (PubMed ID: 17601542)
1. The impact of thiazolidinedione use on outcomes in ambulatory patients with diabetes mellitus and heart failure.
Aguilar D; Bozkurt B; Pritchett A; Petersen NJ; Deswal A
J Am Coll Cardiol; 2007 Jul; 50(1):32-6. PubMed ID: 17601542
[TBL] [Abstract][Full Text] [Related]
2. Thiazolidinediones and congestive heart failure in veterans with type 2 diabetes.
Toprani A; Fonseca V
Diabetes Obes Metab; 2011 Mar; 13(3):276-80. PubMed ID: 21205120
[TBL] [Abstract][Full Text] [Related]
3. Metformin use and mortality in ambulatory patients with diabetes and heart failure.
Aguilar D; Chan W; Bozkurt B; Ramasubbu K; Deswal A
Circ Heart Fail; 2011 Jan; 4(1):53-8. PubMed ID: 20952583
[TBL] [Abstract][Full Text] [Related]
4. Thiazolidinediones and cardiovascular outcomes in older patients with diabetes.
Lipscombe LL; Gomes T; Lévesque LE; Hux JE; Juurlink DN; Alter DA
JAMA; 2007 Dec; 298(22):2634-43. PubMed ID: 18073359
[TBL] [Abstract][Full Text] [Related]
5. Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study.
Masoudi FA; Inzucchi SE; Wang Y; Havranek EP; Foody JM; Krumholz HM
Circulation; 2005 Feb; 111(5):583-90. PubMed ID: 15699279
[TBL] [Abstract][Full Text] [Related]
6. Association between congestive heart failure and hospitalization in patients with type 2 diabetes mellitus receiving treatment with insulin or pioglitazone: a retrospective data analysis.
Rajagopalan R; Rosenson RS; Fernandes AW; Khan M; Murray FT
Clin Ther; 2004 Sep; 26(9):1400-10. PubMed ID: 15531002
[TBL] [Abstract][Full Text] [Related]
7. Diabetes and heart failure: the role of thiazolidinediones in managing these partners in crime.
Leier CV; Haas GJ
J Am Coll Cardiol; 2007 Jul; 50(1):37-9. PubMed ID: 17601543
[No Abstract] [Full Text] [Related]
8. The thiazolidinediones rosiglitazone and pioglitazone and the risk of coronary heart disease: a retrospective cohort study using a US health insurance database.
Ziyadeh N; McAfee AT; Koro C; Landon J; Arnold Chan K
Clin Ther; 2009 Nov; 31(11):2665-77. PubMed ID: 20110009
[TBL] [Abstract][Full Text] [Related]
9. Insulin-sensitizing antihyperglycemic drugs and mortality after acute myocardial infarction: insights from the National Heart Care Project.
Inzucchi SE; Masoudi FA; Wang Y; Kosiborod M; Foody JM; Setaro JF; Havranek EP; Krumholz HM
Diabetes Care; 2005 Jul; 28(7):1680-9. PubMed ID: 15983320
[TBL] [Abstract][Full Text] [Related]
10. Relationship between cumulative dose of thiazolidinediones and clinical outcomes in type 2 diabetic patients with history of heart failure: a population-based cohort study in Taiwan.
Hsiao FY; Tsai YW; Wen YW; Chen PF; Chou HY; Chen CH; Kuo KN; Huang WF
Pharmacoepidemiol Drug Saf; 2010 Aug; 19(8):786-91. PubMed ID: 20607752
[TBL] [Abstract][Full Text] [Related]
11. Risk of stroke with thiazolidinediones: a ten-year nationwide population-based cohort study.
Lu CJ; Sun Y; Muo CH; Chen RC; Chen PC; Hsu CY
Cerebrovasc Dis; 2013; 36(2):145-51. PubMed ID: 24029780
[TBL] [Abstract][Full Text] [Related]
12. Thiazolidinedione use is not associated with worse cardiovascular outcomes: a study in 28,332 high risk patients with diabetes in routine clinical practice: brief title: thiazolidinedione use and mortality.
Roussel R; Hadjadj S; Pasquet B; Wilson PW; Smith SC; Goto S; Tubach F; Marre M; Porath A; Krempf M; Bhatt DL; Steg PG
Int J Cardiol; 2013 Aug; 167(4):1380-4. PubMed ID: 22560911
[TBL] [Abstract][Full Text] [Related]
13. Incidence of cardiovascular events in which 2 thiazolidinediones are used as add-on treatments for type 2 diabetes mellitus in a Taiwanese population.
Wang CC; Chen WL; Kao TW; Chang YW; Loh CH; Chou CC
Clin Ther; 2011 Dec; 33(12):1904-13. PubMed ID: 22118894
[TBL] [Abstract][Full Text] [Related]
14. Antihyperglycemic Medication Use Among Medicare Beneficiaries With Heart Failure, Diabetes Mellitus, and Chronic Kidney Disease.
Patel PA; Liang L; Khazanie P; Hammill BG; Fonarow GC; Yancy CW; Bhatt DL; Curtis LH; Hernandez AF
Circ Heart Fail; 2016 Jul; 9(7):. PubMed ID: 27413035
[TBL] [Abstract][Full Text] [Related]
15. Capitalizing on prescribing pattern variation to compare medications for type 2 diabetes.
Prentice JC; Conlin PR; Gellad WF; Edelman D; Lee TA; Pizer SD
Value Health; 2014 Dec; 17(8):854-62. PubMed ID: 25498781
[TBL] [Abstract][Full Text] [Related]
16. Dose effect of thiazolidinedione on cancer risk in type 2 diabetes mellitus patients: a six-year population-based cohort study.
Lin HC; Hsu YT; Kachingwe BH; Hsu CY; Uang YS; Wang LH
J Clin Pharm Ther; 2014 Aug; 39(4):354-60. PubMed ID: 24661226
[TBL] [Abstract][Full Text] [Related]
17. Cancer risks in thiazolidinedione users compared to other anti-diabetic agents.
Koro C; Barrett S; Qizilbash N
Pharmacoepidemiol Drug Saf; 2007 May; 16(5):485-92. PubMed ID: 17192841
[TBL] [Abstract][Full Text] [Related]
18. Review article: Thiazolidinediones and heart failure.
Chaggar PS; Shaw SM; Williams SG
Diab Vasc Dis Res; 2009 Jul; 6(3):146-52. PubMed ID: 20368206
[TBL] [Abstract][Full Text] [Related]
19. Thiazolidinediones in type 2 diabetes: a cardiology perspective.
Khanderia U; Pop-Busui R; Eagle KA
Ann Pharmacother; 2008 Oct; 42(10):1466-74. PubMed ID: 18698014
[TBL] [Abstract][Full Text] [Related]
20. Risk of hospitalization for heart failure associated with thiazolidinedione therapy: a medicaid claims-based case-control study.
Hartung DM; Touchette DR; Bultemeier NC; Haxby DG
Pharmacotherapy; 2005 Oct; 25(10):1329-36. PubMed ID: 16185176
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]